Key regions: Germany, South Korea, France, United States, United Kingdom
The demand for anti-coagulants in Southern Asia has been steadily increasing in recent years due to various factors.
Customer preferences: One of the main reasons for the growing demand for anti-coagulants is the increasing prevalence of cardiovascular diseases in the region. As a result, patients are opting for anti-coagulants as a preventive measure to reduce the risk of blood clots and stroke. Additionally, the aging population in the region is also contributing to the rise in demand for anti-coagulants.
Trends in the market: India and China are the largest markets for anti-coagulants in Southern Asia. In India, the market is dominated by vitamin K antagonists, while in China, non-vitamin K antagonist oral anti-coagulants are gaining popularity. The trend towards non-vitamin K antagonist oral anti-coagulants is also seen in other countries in the region, such as South Korea and Taiwan. This shift is primarily due to the convenience of these drugs, which do not require frequent monitoring and have fewer interactions with other medications.
Local special circumstances: In addition to the rising prevalence of cardiovascular diseases and aging population, there are other local factors that are driving the growth of the anti-coagulants market in Southern Asia. For instance, the high incidence of deep vein thrombosis (DVT) in India is contributing to the demand for anti-coagulants. Furthermore, the increasing incidence of atrial fibrillation, particularly in China and India, is expected to further boost the demand for anti-coagulants in the region.
Underlying macroeconomic factors: The growing middle class and increasing healthcare spending in Southern Asia are also contributing to the growth of the anti-coagulants market. As the population becomes more affluent, there is a greater willingness to spend on preventive healthcare measures. Additionally, the increasing availability of health insurance in the region is also driving demand for anti-coagulants, as more people are able to afford these drugs.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
